Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-Negative Breast Carcinoma
Interventions: DRUG: Carboplatin|DRUG: Gamma-Secretase Inhibitor RO4929097|OTHER: Laboratory Biomarker Analysis|DRUG: Paclitaxel|OTHER: Pharmacological Study|PROCEDURE: Therapeutic Conventional Surgery
Sponsor: National Cancer Institute (NCI)